NW-301D

Other Medications

4 Clinical Trials

Description

NW-301D is an experimental therapy being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being investigated as part of a combination approach with another experimental therapy, NW-301V. The trials are in Phase 1, which means they are primarily focused on determining the safety of the treatment and finding the right dose. These trials are recruiting patients. The specific trials involving NW-301D are looking at patients whose tumors have a specific type of KRAS mutation (G12D). NW-301D is being developed by researchers at Peking University.

Mechanism of Action

NW-301D is a type of cell therapy. It involves modifying a patient's own T cells (a type of immune cell) to target cancer cells. The specific way NW-301D works is being investigated in clinical trials, but it is designed to enhance the ability of T cells to recognize and attack cancer cells, particularly those with KRAS mutations.

Side Effects

As NW-301D is an experimental therapy in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. Patients participating in these trials will be closely monitored for any adverse events. Common side effects associated with T cell therapies and the lymphodepleting regimen used in these trials can include flu-like symptoms Fatigue Infusion reactions And potential effects on the immune system. More specific side effects related to NW-301D are being determined in the ongoing trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06484556 Phase 1
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
China
NCT06484790 Phase 1
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
China
NCT06478251 Phase 1
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
China
NCT06956261 Phase 1
Not yet recruiting
NW-301 TCR-T in Patients With Advanced Solid Tumor
China

Quick Info

CategoryOther Medications
Clinical Trials4
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.